(Q39608521)

13 September 2017

Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome (English)

1 reference

13 September 2017

0 references

10

1 reference

13 September 2017

12

Angela Tincani

1 reference

13 September 2017

2

Mara Taraborelli

1 reference

13 September 2017

3

Laura Andreoli

1 reference

13 September 2017

11

Amelia Ruffatti

1 reference

13 September 2017

4

Marta Tonello

1 reference

13 September 2017

9

Vittorio Pengo

1 reference

13 September 2017

Entela Nuri

1

1 reference

13 September 2017

Maria Gerosa

5

1 reference

13 September 2017

Antonia Calligaro

6

1 reference

13 September 2017

Lorenza Maria Argolini

7

1 reference

13 September 2017

Rajesh Kumar

8

1 reference

13 September 2017

language of work or name

1 reference

13 July 2016

1 reference

13 September 2017

1 reference

13 September 2017

65

1 reference

13 September 2017

1

1 reference

13 September 2017

17-24

1 reference

https://scigraph.springernature.com/pub.10.1007/s12026-016-8812-z

13 September 2017

0 references

cites work

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Hydroxychloroquine treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Biochemical characterization of ADP-ribose polymer metabolism in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Mode of action of hydroxychloroquine in RA-evidence of an inhibitory effect on toll-like receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Antiphospholipid Syndrome Clinical Research Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Clinical course of high-risk patients diagnosed with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

On the inhibitory effect of chloroquine on blood platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (third of three parts)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-016-8812-Z

Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity?

21 January 2018

1 reference

12 December 2020

The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.

1 reference

12 December 2020

Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients

1 reference

12 December 2020

Antimalarial agents: closing the gate on Toll-like receptors?

1 reference

12 December 2020

The efficacy of antimalarials in systemic lupus erythematosus

1 reference

12 December 2020

APS--more systemic disease than SLE

1 reference

12 December 2020

Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties.

1 reference

12 December 2020

Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?

1 reference

12 December 2020

Anti-beta 2-glycoprotein I antibodies: a marker of antiphospholipid syndrome?

1 reference

12 December 2020

Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy

1 reference

12 December 2020

Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies

1 reference

12 December 2020

Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.

1 reference

12 December 2020

Inhibition by chloroquine of the class II major histocompatibility complex-restricted presentation of endogenous antigens varies according to the cellular origin of the antigen-presenting cells, the nature of the T-cell epitope, and the responding T

1 reference

12 December 2020

Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial

1 reference

12 December 2020

The anticardiolipin syndrome

1 reference

12 December 2020

10.1007/S12026-016-8812-Z

Identifiers

DOI

1 reference

13 September 2017

1 reference